Metsera Inc. (NASDAQ:MTSR) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Metsera Inc. has received a consensus rating of "Buy" from seven analysts, with an average target price of $63.50.
• Recent brokerage activity includes Wells Fargo setting a price objective of $65.00 and Guggenheim raising their target from $56.00 to $62.00.
• Institutional investors, like Osaic Holdings and BNP Paribas, have significantly increased their stakes in Metsera, indicating growing confidence in the company.

Metsera Inc. (NASDAQ:MTSR - Get Free Report) has been given a consensus recommendation of "Buy" by the seven analysts that are covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $63.50.

A number of brokerages have recently commented on MTSR. Wells Fargo & Company began coverage on shares of Metsera in a research note on Friday, June 20th. They set an "overweight" rating and a $65.00 price objective on the stock. Wall Street Zen cut shares of Metsera from a "hold" rating to a "sell" rating in a research note on Tuesday. Guggenheim raised their price objective on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Cantor Fitzgerald reissued an "overweight" rating on shares of Metsera in a research note on Wednesday, September 3rd. Finally, Leerink Partnrs raised shares of Metsera to a "strong-buy" rating in a research note on Tuesday, September 9th.

Metsera Trading Down 1.1%

Shares of NASDAQ:MTSR opened at $53.00 on Wednesday. Metsera has a twelve month low of $12.30 and a twelve month high of $54.47. The company's 50 day moving average is $35.91 and its 200 day moving average is $29.52.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Institutional Investors Weigh In On Metsera

A number of institutional investors have recently added to or reduced their stakes in MTSR. Osaic Holdings Inc. grew its stake in Metsera by 45.5% in the 2nd quarter. Osaic Holdings Inc. now owns 946 shares of the company's stock valued at $27,000 after acquiring an additional 296 shares during the period. BNP Paribas Financial Markets grew its stake in Metsera by 100.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company's stock valued at $46,000 after acquiring an additional 800 shares during the period. Strs Ohio acquired a new stake in Metsera in the 1st quarter valued at $76,000. Virtus Investment Advisers LLC acquired a new stake in Metsera in the 2nd quarter valued at $77,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Metsera in the 2nd quarter valued at $122,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.